New Injectables For Knee OA Fuel US Joint Fluid Market

Although several factors have recently slowed growth in the US market for joint fluid replacement, it remains large and vastly underpenetrated with an estimated 15.8 million knee osteoarthritis patients who are hoping to delay the need for a total knee arthroplasty. With a growing number of products in the pipeline and increasing adoption of new single-injection products, the US joint fluid market is projected to increase from approximately $924.4 million in 2015 to more than $1.07 billion by 2019, a CAGR of 4%.

Over half of US adults diagnosed with knee osteoarthritis (OA) will eventually undergo knee replacement and an estimated 4 million adults in the US currently live with a total knee. Knee patients suffer about five years before seeing an orthopedic surgeon and as long as 10 years before undergoing surgery, although this is changing. While patients with arthritic knees are encouraged to hold off as long as possible, many demand intervention at an earlier age because there are few treatments available for alleviating their pain and limited mobility. BioMedGPS estimates the US market for total knee replacement will close in on $4.3 billion by the end of 2015.

With no proven treatment in sight for delaying the onset of OA, knee pain suffers will try a variety of over-the-counter supplements (e.g., glucosamine and chondroitin sulfate, vitamins E or...

More from Archive

More from Medtech Insight

Execs On The Move: 5-9 May 2025

 
• By 

An interactive look at recent executive-level company changes and promotions in the medical device and diagnostics industries.

TRiCares Tricuspid Valve Replacement System Reduces Regurgitation In First-In-Human Study

 

TRiCares presented data from the first-in-human study for its tricuspid valve replacement system – Topaz – at EuroPCR 2025 on 22 May.

Swiss Medtechs Advised To Work On US Tariff Mitigation Strategies

 
• By 

The US’ 90-day suspension of higher “reciprocal tariffs” will expire on 9 July, raising fears that the 31% tariff rate on Swiss medtech and other goods exported to the US might make a comeback. While the tariff situation changes on an almost daily basis, medtechs should forearm for any eventually, say local business organizations.